RayKnowChina Research Map
Shortlist

HarbinHarbin Medical University

First Affiliated Hospital of Harbin Medical University

哈尔滨医科大学附属第一医院

Listed for 23 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Harbin Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌31 papers led
  2. Lung cancer肺癌25 papers led
  3. Pancreatic cancer胰腺癌23 papers led
  4. Breast cancer乳腺癌23 papers led
  5. Glioma胶质瘤35 papers led
  6. Hepatoblastoma肝母细胞瘤0 papers led
  7. Retinoblastoma视网膜母细胞瘤2 papers led
  8. Osteosarcoma骨肉瘤21 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  10. Neuroblastoma神经母细胞瘤3 papers led
  11. Ewing sarcoma尤文肉瘤1 paper led
  12. Multiple myeloma多发性骨髓瘤4 papers led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  14. Lymphoma淋巴瘤1 paper led1 open trial led
  15. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  16. Moyamoya disease烟雾病2 papers led
  17. Coronary heart disease冠心病8 papers led
  18. Scoliosis脊柱侧弯2 papers led
  19. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  20. Amyotrophic lateral sclerosis肌萎缩侧索硬化症11 papers led
  21. Behçet disease白塞病1 paper led
  22. IgA nephropathyIgA 肾病2 papers led
  23. Hirschsprung disease先天性巨结肠1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Chordoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Congenital heart disease, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 31 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
31
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 8820222023: 7720232024: 7720242025: 332025

4 hospitals in Harbin for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led31
  1. A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma.2025Cell death and differentiationFree full text
  2. Periodontitis and Hepatocellular Carcinoma: A Two-Sample Mendelian Randomisation Study.2025International dental journalFree full text
  3. Melanin@PLGA/Nuciferine Nanoparticles for Enhanced Photothermal Therapy of Hepatocellular Carcinoma by Promoting Autophagy.2025International journal of nanomedicineFree full text
  4. Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.2024Digestive diseases and sciences
  6. RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma.2024Experimental & molecular medicineFree full text
  7. FBW7-Mediated Degradation of CHD3 Suppresses Hepatocellular Carcinoma Metastasis and Stemness to Enhance Oxaliplatin Sensitivity.2024Frontiers in bioscience (Landmark edition)
  8. Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC.2024Hepatology (Baltimore, Md.)Free full text
  9. RRP8, associated with immune infiltration, is a prospective therapeutic target in hepatocellular carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  10. Integrative transcriptome analysis identifies a crotonylation gene signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.2024Journal of cellular and molecular medicineFree full text
  11. A TiN-based nanophotosensitizer for enhanced photothermal therapy with the aid of ultrasound.2023Biochemical and biophysical research communications
  12. Alternative splicing of IRF3 plays an important role in the development of hepatocarcinoma.2023EpigeneticsFree full text
  13. Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  14. TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages.2023Journal of experimental & clinical cancer research : CRFree full text
  15. Triptonide inhibits growth and metastasis in HCC by suppressing EGFR/PI3K/AKT signaling.2023Neoplasma
  16. Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.2023Oncogene
  17. RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway.2023Oncogene
  18. Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  19. Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib.2022Cell death & diseaseFree full text
  20. Long non-coding RNA TPTEP1 exerts inhibitory effects on hepatocellular carcinoma by impairing microRNA-454-3p-mediated DLG5 downregulation.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  21. ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma.2022Disease markersFree full text
  22. Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matc2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  23. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  24. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.2022Journal of experimental & clinical cancer research : CRFree full text
  25. Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.2022Scandinavian journal of gastroenterology
  26. Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  27. TNF-α/NF-κB signaling epigenetically represses PSD4 transcription to promote alcohol-related hepatocellular carcinoma progression.2021Cancer medicineFree full text
  28. Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  29. CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway.2021FEBS open bioFree full text
  30. The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma.2021Free radical biology & medicine
  31. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway.2021Neoplasma
Chinese-language papers (not in the count)1
  1. [Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status2
  1. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  2. the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular CarcinomaCompletedNCT01717066Study siteN/AStart 2012-11

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 25 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 2220232024: 9920242025: 552025

4 hospitals in Harbin for lung cancer251 hospitals in China for lung cancer

No open trial on lung cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurologyNeurosurgeryPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led25
  1. MYBL2 regulates the expression of CENPF in lung adenocarcinoma and promotes tumor development and metastasis through AKT pathway activation.2025European journal of medical researchFree full text
  2. CircRAPGEF5 Promotes LUAD by Mediating the HOXC6 Stability.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer.2025Journal of experimental & clinical cancer research : CRFree full text
  4. M2 macrophage-derived exosomes promote cell proliferation, migration and EMT of non-small cell lung cancer by secreting miR-155-5p.2025Molecular and cellular biochemistry
  5. Causal Associations Between Cystatin and Lung Cancer: A Two-Sample Mendelian Randomization Study.2025The clinical respiratory journalFree full text
  6. Non-invasively Discriminating the Pathological Subtypes of Non-small Cell Lung Cancer with Pretreatment 18F-FDG PET/CT Using Deep Learning.2024Academic radiology
  7. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicineFree full text
  8. SLC12A8 promotes the migration and invasion of non-small cell lung cancer (NSCLC) cells.2024General physiology and biophysics
  9. Impact of SARS-CoV-2 infection on immune cell cuproptosis in patients with lung adenocarcinoma via glutamine regulation.2024International immunopharmacology
  10. Exosomal miR-20b-5p Induces EMT and Enhances Progression in Non-Small Cell Lung Cancer Via TGFBR2 Downregulation.2024Journal of biochemical and molecular toxicology
  11. Learning curve for double-port video-assisted thoracoscopic lung segmentectomy: a propensity score matching study.2024Journal of cardiothoracic surgeryFree full text
  12. Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.2024Journal of cellular and molecular medicineFree full text
  13. Correlation between CT spectral quantitative parameters and expression levels of HIF-1α and ALX1 in non-small cell lung cancer.2024MedicineFree full text
  14. N6-methyladenosine-mediated LINC01087 promotes lung adenocarcinoma progression by regulating miR-514a-3p to upregulate centrosome protein 55.2024The Kaohsiung journal of medical sciencesFree full text
  15. Targeting Pokemon is a novel strategy to suppress cancer aggressiveness of non-small cell lung cancer: Identification of Pokemon as ideal target for developing anti-NSCLC drugs.2023Archives of biochemistry and biophysics
  16. Association of plasma branched-chain amino acid with multiple cancers: A mendelian randomization analysis.2023Clinical nutrition (Edinburgh, Scotland)
  17. E3 ubiquitin-protein ligase 2 inhibits cell proliferation, migration, and invasion of non-small cell lung cancer through ubiquitination of Notch1.2022Acta histochemica
  18. A triple-classification for the evaluation of lung nodules manifesting as pure ground-glass sign: a CT-based radiomic analysis.2022BMC medical imagingFree full text
  19. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.2022BMC pulmonary medicineFree full text
  20. Biological functions of nuclear-localized insulin receptor (IR) on A549 lung cancer cells.2022Endokrynologia Polska
  21. Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma.2022Neoplasma
  22. LncRNA MALAT1 aggravates oxygen-glucose deprivation/reoxygenation-induced neuronal endoplasmic reticulum stress and apoptosis via the miR-195a-5p/HMGA1 axis.2021Biological researchFree full text
  23. Clinical significance of expression level of CX3CL1-CX3CR1 axis in bone metastasis of lung cancer.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  24. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.2021Journal of bioenergetics and biomembranes
  25. Function and mechanism exploration of zinc finger protein 64 in lung adenocarcinoma cell growth and metastasis.2021Journal of receptor and signal transduction research
All its trials on ClinicalTrials.gov, any status3
  1. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerTerminatedNCT06897579Study sitePhase 2Start 2025-04
  2. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  3. A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerTerminatedNCT03745222Study sitePhase 3Start 2019-05

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 23 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
23
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 8820232024: 3320242025: 552025

3 hospitals in Harbin for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led23
  1. RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement.2026OncogeneFree full text
  2. Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  3. The role of LncRNA-MANCR induced by HIF-1α drive the malignant progression of pancreatic cancer by targeting miRNA-494/SIRT1 signaling axis under hypoxic conditions.2025Cancer gene therapy
  4. The lncRNA ST18-AS1 suppresses pancreatic cancer progression by enhancing ST18 mRNA stability through anchoring FUS in the cytoplasm.2025Oncogene
  5. Alcohol-induced C/EBP β-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway.2025Oncogene
  6. TRPM4 expression predicts prognosis and modulates the immune microenvironment in pancreatic adenocarcinoma.2025Scientific reportsFree full text
  7. Revealing a cancer-associated fibroblast-based risk signature for pancreatic adenocarcinoma through single-cell and bulk RNA-seq analysis.2024AgingFree full text
  8. LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc.2024Carcinogenesis
  9. Dual Starvations Induce Pyroptosis for Orthotopic Pancreatic Cancer Therapy through Simultaneous Deprivation of Glucose and Glutamine.2024Journal of the American Chemical Society
  10. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular Vesicles Cargo MiR-4736.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  11. The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment.2023British journal of cancerFree full text
  12. Clinical application of Al18F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to 18F-FDG.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  13. DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer.2023Cancer letters
  14. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.2023Journal of cancer research and clinical oncologyFree full text
  15. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer.2023Journal of translational medicineFree full text
  16. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer.2023Molecular cancerFree full text
  17. Identification of MIR600HG/hsa-miR-342-3p/ANLN network as a potential prognosis biomarker associated with lmmune infiltrates in pancreatic cancer.2023Scientific reportsFree full text
  18. Diabetic Ferroptosis and Pancreatic Cancer: Foe or Friend?2022Antioxidants & redox signaling
  19. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer.2022Cancer scienceFree full text
  20. Identification of hub genes in chronic pancreatitis and analysis of association with pancreatic cancer via bioinformatic analysis.2022General physiology and biophysics
  21. Dictamnine inhibits pancreatic cancer cell growth and epithelial-mesenchymal transition by blocking the PI3K/AKT signaling pathway.2022Neoplasma
  22. Invadopodia: A potential target for pancreatic cancer therapy.2021Critical reviews in oncology/hematology
  23. Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer.2021Journal of cancer research and therapeutics
Chinese-language papers (not in the count)1
  1. [Current status and controversy of neoadjuvant therapy in pancreatic cancer].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota RegulationStatus unknownNCT04203459Lead sponsorStart 2019-10
  2. Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.Status unknownNCT03267173Lead sponsorEarly phase 1Start 2017-06
  3. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  4. Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic CancerStatus unknownNCT03792932Study siteN/AStart 2019-02

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 23 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
23
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 1120222023: 4420232024: 7720242025: 662025

4 hospitals in Harbin for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyNeurosurgery
Papers it led23
  1. A survival analysis of T1 stage breast cancer and nomogram development: based on the SEER database.2025Clinics (Sao Paulo, Brazil)Free full text
  2. Survival analysis of metachronous bilateral ectopic breast cancer utilizing the SEER database and the pioneering construction of a nomogram model.2025European journal of medical researchFree full text
  3. Immune-based molecular subtyping of triple-negative breast cancer via SNF-CC and functional validation of key immune-associated genes.2025Functional & integrative genomics
  4. Expression and prognostic impact of hypoxia- and immune escape-related genes in triple-negative breast cancer: A comprehensive analysis.2025International immunopharmacology
  5. C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer.2025Journal of experimental & clinical cancer research : CRFree full text
  6. Nomogram construction and survival analysis in T3N0M0 breast cancer: a SEER population-based analysis.2025Scientific reportsFree full text
  7. A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database.2024Breast cancer (Tokyo, Japan)Free full text
  8. Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization.2024Cancer causes & control : CCC
  9. Nomograms for predicting recurrence of HER2-positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics.2024Cancer medicineFree full text
  10. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicineFree full text
  11. CircRNA hsa_circ_0003528/miR-215 is considered a potential target for predictive prognosis and therapy for triple-negative breast cancer.2024Molecular biology reports
  12. Long non‑coding RNA DANCR aggravates breast cancer through the miR‑34c/E2F1 feedback loop.2024Molecular medicine reportsFree full text
  13. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations.2024World journal of surgical oncologyFree full text
  14. Association of plasma branched-chain amino acid with multiple cancers: A mendelian randomization analysis.2023Clinical nutrition (Edinburgh, Scotland)
  15. Silencing MFHAS1 Induces Pyroptosis via the JNK-activated NF-κB/Caspase1/ GSDMD Signal Axis in Breast Cancer.2023Current pharmaceutical design
  16. ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat.2023European journal of cell biology
  17. Clinicopathological analysis and prognostic treatment study of angiosarcoma of the breast: a SEER population-based analysis.2023World journal of surgical oncologyFree full text
  18. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.2022Journal of experimental & clinical cancer research : CRFree full text
  19. Analysis of prognostic risk factors in 3427 patients with invasive ductal carcinoma of breast: Results based on the SEER database.2021Asian journal of surgery
  20. NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells.2021Journal of cellular biochemistry
  21. The nomogram based on the 6-lncRNA model can promote the prognosis prediction of patients with breast invasive carcinoma.2021Scientific reportsFree full text
  22. Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer.2021TheranosticsFree full text
  23. Long-term oncologic safety of immediate reconstructive surgery in patients with invasive breast cancer: a retrospective matched-cohort study.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Intestinal Microbiota of Breast Cancer Patients Undergoing ChemotherapyStatus unknownNCT04138979Lead sponsorStart 2019-09
  2. TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Study sitePhase 3Start 2025-07

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 35 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.5%.

Papers led
35
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 8820222023: 6620232024: 4420242025: 10102025

4 hospitals in Harbin for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicinePathology / laboratory medicineNeurology

Over half of these papers are lab or animal studies.

Papers it led35
  1. Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.2025Cancer gene therapy
  2. Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma.2025Current medicinal chemistryFree full text
  3. Research landscape of glioma and inflammation over the past two decades.2025Frontiers in immunologyFree full text
  4. HSPA5-mediated glioma hypoxia tolerance promotes M2 macrophage polarization under hypoxic microenvironment.2025International immunopharmacology
  5. Bone morphogenetic protein 1 as a macromolecular pan-cancer biomarker modulating the immune microenvironment and malignant phenotypes in glioblastoma.2025International journal of biological macromolecules
  6. Integrative spatial multi-omics identifies the TEK receptor tyrosine kinase as a central biomacromolecule of endothelial-immune interactions in glioblastoma.2025International journal of biological macromolecules
  7. Ubiquitin-conjugating enzyme E2S decreases the sensitivity of glioblastoma cells to temozolomide by upregulating PGAM1 via the interaction with OTUB2.2025International journal of biological macromolecules
  8. Hypoxia-Inducible Factor-1α Regulates BNIP3-Dependent Mitophagy and Mediates Metabolic Reprogramming Through Histone Lysine Lactylation Modification to Affect Glioma Proliferation and Invasion.2025Journal of biochemical and molecular toxicology
  9. Ho(III)-coordination Complex: Fluorescence Performances and Combined with Captopril-Hydrogels against Glioma.2025Journal of fluorescence
  10. Investigating the Aidi injection mechanism for low-grade glioma based on the network pharmacology approach, The Cancer Genome Atlas (TCGA), and molecular docking technology.2025MedicineFree full text
  11. Integrated analysis of bulk and single-cell RNA sequencing reveals the impact of nicotinamide and tryptophan metabolism on glioma prognosis and immunotherapy sensitivity.2024BMC neurologyFree full text
  12. UBE2S facilitates glioblastoma progression through activation of the NF-κB pathway via attenuating K11-linked ubiquitination of AKIP1.2024International journal of biological macromolecules
  13. Etomidate inhibits tumor growth of glioblastoma by regulating M1 macrophage polarization.2024Metabolic brain disease
  14. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.2024Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  15. Immunostimulant In Situ Fibrin Gel for Post-operative Glioblastoma Treatment by Macrophage Reprogramming and Photo-Chemo-Immunotherapy.2023ACS applied materials & interfaces
  16. Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.2023BMC cancerFree full text
  17. Evaluating glioma-associated microRNA by complementation on a biological nanosensor.2023Biotechnology and applied biochemistry
  18. LncRNA as potential biomarker and therapeutic target in glioma.2023Molecular biology reports
  19. Prevalence, risk factors and prognostic value of anxiety and depression in recurrent glioma patients.2023Psychology, health & medicine
  20. Identification of DNA Damage Repair Gene Signature as a Novel Prognostic Marker in Glioblastoma Multiforme.2023World neurosurgery
  21. Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.2022BioengineeredFree full text
  22. The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.2022Current pharmaceutical designFree full text
  23. Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme.2022Frontiers in immunologyFree full text
  24. CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway.2022Life sciences
  25. Chelerythrine inhibits the progression of glioblastoma by suppressing the TGFB1-ERK1/2/Smad2/3-Snail/ZEB1 signaling pathway.2022Life sciences
  26. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  27. Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.2022Technology in cancer research & treatmentFree full text
  28. Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-Dependent Pyroptosis in Glioblastoma Multiforme.2022World neurosurgery
  29. IL-24 inhibits the malignancy of human glioblastoma cells via destabilization of Zeb1.2021Biological chemistry
  30. Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy.2021Cell death & diseaseFree full text
  31. Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma.2021Cell death & diseaseFree full text
  32. TMEM2 Combined with IDH and 1p19q in Refining Molecular Subtypes for Predicting Survival of Patients with Glioma.2021DNA and cell biology
  33. MSH6 Aggravates the Hypoxic Microenvironment via Regulating HIF1A to Promote the Metastasis of Glioblastoma Multiforme.2021DNA and cell biology
  34. Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors: A randomized controlled trial.2021MedicineRCTFree full text
  35. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma.2021Pathology oncology research : PORFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Harbin for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Harbin for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 21 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 3320232024: 4420242025: 552025

6 hospitals in Harbin for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology

Over half of these papers are lab or animal studies.

Papers it led21
  1. Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy.2025Anticancer research
  2. Harmine exerts anticancer effects through the ROS/p38 axis to induce autophagy and apoptosis in osteosarcoma.2025Bioorganic chemistry
  3. Extraskeletal Ewing Sarcoma of the Abdominopelvic Cavity Revealed by 18 F-FDG PET/CT.2025Clinical nuclear medicine
  4. A strategy for challenging tumorous bone regeneration by borosilicate bioactive glass boosting moderate magnetic hyperthermia.2025Nature communicationsFree full text
  5. Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma.2024Cell communication and signaling : CCSFree full text
  7. A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.2024Frontiers in immunologyFree full text
  8. M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma.2024Oncogene
  9. Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis.2024Toxicology and applied pharmacology
  10. Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma.2023BMC medical genomicsFree full text
  11. RING finger gene 180 inhibits osteosarcoma progression through regulating chromobox homolog 4 ubiquitination.2023Cell cycle (Georgetown, Tex.)Free full text
  12. PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.2023Journal of orthopaedic surgery and researchFree full text
  13. Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition.2022Cell death & diseaseFree full text
  14. The Subcellular Localization of IncRNA FAM230B in Osteosarcoma and Its Interaction with Early miR-203.2022Critical reviews in eukaryotic gene expression
  15. LncRNA BACE1-AS promotes the progression of osteosarcoma through miR-762/SOX7 axis.2022Molecular biology reports
  16. Hydroxygenkwanin suppresses proliferation, invasion and migration of osteosarcoma cells via the miR‑320a/SOX9 axis.2022Molecular medicine reportsFree full text
  17. Involvement of miR-769-5p/Retinoic Acid Receptor Responder 1 Axis in the Progression of Osteosarcoma: Characterization of Potential Therapeutic Targets.2022Pharmacology
  18. Accurate Identification and Early Diagnosis of Osteosarcoma through CRISPR-Cas12a-Based Average Telomerase Activity Detection.2021ACS synthetic biology
  19. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.2021BMC cancerFree full text
  20. NPR3, transcriptionally regulated by POU2F1, inhibits osteosarcoma cell growth through blocking the PI3K/AKT pathway.2021Cellular signalling
  21. Long non‑coding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR‑29a‑3p.2021Oncology reportsFree full text
Earlier papers (2016–2020)26
  1. Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.2020Experimental cell research
  2. Downregulation of lncRNA SNHG12 reversed IGF1R-induced osteosarcoma metastasis and proliferation by targeting miR-195-5p.2020Gene
  3. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.2020Journal of clinical laboratory analysis
  4. Construction and Validation of Nomograms for Predicting the Prognosis of Juvenile Osteosarcoma: A Real-World Analysis in the SEER Database.2020Technology in cancer research & treatment
  5. NFIL3 Acts as a Nuclear Factor to Increase Osteosarcoma Progression.2019BioMed research international
  6. Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma.2019Drug delivery
  7. Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously competing with miR-199a-3p.2019IUBMB life
  8. Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.2019International journal of biological sciences
  9. SIRT1-ZEB1-positive feedback promotes epithelial-mesenchymal transition process and metastasis of osteosarcoma.2019Journal of cellular biochemistry
  10. Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells.2019Oncology reports
  11. miR-590-3p is a novel microRNA which suppresses osteosarcoma progression by targeting SOX9.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  12. Chimaphilin inhibits human osteosarcoma cell invasion and metastasis through suppressing the TGF-β1-induced epithelial-to-mesenchymal transition markers via PI-3K/Akt, ERK1/2, and Smad signaling pathways.2018Canadian journal of physiology and pharmacology
  13. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.2018Cancer science
  14. Construction and analysis of a ceRNA‑ceRNA network reveals two potential prognostic modules regulated by hsa‑miR‑335‑5p in osteosarcoma.2018International journal of molecular medicine
  15. MicroRNA-129-5p suppresses cell proliferation, migration and invasion via targeting ROCK1 in osteosarcoma.2018Molecular medicine reports
  16. Deoxyelephantopin Induces Reactive Oxygen Species-Mediated Apoptosis and Autophagy in Human Osteosarcoma Cells.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  17. A novel mechanism of mTORC1-mediated serine/glycine metabolism in osteosarcoma development.2017Cellular signalling
  18. MicroRNA-492 overexpression exerts suppressive effects on the progression of osteosarcoma by targeting PAK7.2017International journal of molecular medicine
  19. Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis.2017Oncology reports
  20. Circular RNA hsa-circ-0016347 promotes proliferation, invasion and metastasis of osteosarcoma cells.2017Oncotarget
  21. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.2016Cancer biomarkers : section A of Disease markers
  22. A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.2016International journal of molecular medicine
  23. Identification of CD20, ECM, and ITGA as Biomarkers for Osteosarcoma by Integrating Transcriptome Analysis.2016Medical science monitor : international medical journal of experimental and clinical research
  24. Relationship Between P15 Gene Mutation and Formation and Metastasis of Malignant Osteosarcoma.2016Medical science monitor : international medical journal of experimental and clinical research
  25. Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3.2016Molecular biology reports
  26. MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Harbin for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

7 hospitals in Harbin for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Harbin for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Harbin for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Risk Stratification and MRD-driven Maintenance for MM After ASCT
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06697483

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantRelapse & resistance

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Harbin for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibody & targeted drugsPhiladelphia chromosome & geneticsCAR-T & cell therapy
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 1 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Harbin for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
    Phase
    Not given
    Started
    2018-03
    Posted
    Registry
    NCT03494296

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Harbin Medical UniversityHarbin

  2. Recruiting
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06973187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Harbin for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

1 hospital in Harbin for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Posted
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGeneticsRevascularisation surgeryImaging & blood flow
Departments in papersNeurologyNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 8 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
8
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 3320242025: 002025

3 hospitals in Harbin for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07521007

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07110415

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai

  3. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Posted
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led8
  1. Application effect of task-oriented multi-dimensional nursing intervention in patients with coronary atherosclerotic heart disease and concurrent hypertension.2024African health sciencesFree full text
  2. Association between Troponin Elevation and Decreased Myocardial Blood Flow Reserve in Patients without Obstructive Coronary Artery Disease.2024CardiologyFree full text
  3. Prognostic value of computed tomography-derived fractional flow reserve in patients with diabetes mellitus and unstable angina.2024Cardiovascular diabetologyFree full text
  4. Predicting coronary artery disease by carotid color doppler ultrasonography.2023European review for medical and pharmacological sciences
  5. Association of marine PUFAs intakes with cardiovascular disease, all-cause mortality, and cardiovascular mortality in American adult male patients with dyslipidemia: the U.S. National Health and Nutrition Examination Survey, 2001 to 2016.2023Nutrition journalFree full text
  6. Characteristics of coronary artery ectasia and accompanying plaques: an optical coherence tomography study.2023The international journal of cardiovascular imagingFree full text
  7. Influence of obstructive sleep apnoea on coronary artery disease in a Chinese population.2022The Journal of international medical researchFree full text
  8. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR).2021Platelets
Chinese-language papers (not in the count)2
  1. [Study on the procoagulant characteristics of microparticles in acute myocardial infarction].2024Zhonghua wei zhong bing ji jiu yi xue
  2. [Update on the role and evaluation index of perivascular adipose tissue in coronary atherosclerosis].2021Zhonghua xin xue guan bing za zhi
All its trials on ClinicalTrials.gov, any status14
  1. Effect of FFRCT-angio in Functional Diagnosis of Coronary Artery StenosisStatus unknownNCT04493086Lead sponsorStart 2020-10
  2. Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery DiseaseCompletedNCT04001894Lead sponsorPhase 4Start 2019-07
  3. Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual HypertriglyceridemiaStatus unknownNCT03610321Lead sponsorPhase 2/Phase 3Start 2019-09
  4. Efficacy and Safety of Low-dose TicagrelorCompletedNCT03381742Lead sponsorPhase 2/Phase 3Start 2017-12
  5. Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery DiseaseStatus unknownNCT02889549Lead sponsorPhase 2/Phase 3Start 2016-08
  6. A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisRecruitingNCT07521007Study sitePhase 2Start 2026-07
  7. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac DysfunctionRecruitingNCT07110415Study sitePhase 4Start 2025-11
  8. Registry of Multicenter Brain-Heart Comorbidity in ChinaRecruitingNCT05961748Study siteStart 2012-01
  9. Efficacy and Safety of Colchicine After PCIActive, not recruitingNCT06472908Study sitePhase 3Start 2024-07
  10. Phitys I™ Percutaneous Left Ventricular Assist System StudyStatus unknownNCT06357026Study siteN/AStart 2024-04
  11. Risk Evaluation by COronary CTA and Artificial IntelliGence Based fuNctIonal analyZing tEchniques - IIStatus unknownNCT05856110Study siteStart 2023-07
  12. CorVad Percutaneous Ventricular Assist System StudyStatus unknownNCT06198998Study siteN/AStart 2023-10
  13. Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IStatus unknownNCT05884008Study siteStart 2023-05
  14. Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for Physiological MeasurementsCompletedNCT05417763Study siteStart 2022-02

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 2 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Harbin for scoliosis107 hospitals in China for scoliosis

No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

3 hospitals in Harbin for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 11 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 1.4%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 3320242025: 662025

3 hospitals in Harbin for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led11
  1. COMM domain containing 4 inhibits hephaestin and ferroportin to enhance neuronal ferroptosis by disturbing the Cu-Fe balance in amyotrophic lateral sclerosis.2025Brain research
  2. Inhibition of Salt-Inducible Kinase 2 Protects Motor Neurons From Degeneration in ALS by Activating Autophagic Flux and Enhancing mTORC1 Activity.2025CNS neuroscience & therapeuticsFree full text
  3. Integrative genomics and functional immunology reveal Clostridia species as modulators of neuroinflammation in amyotrophic lateral sclerosis.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  4. Fisetin Attenuates Mutant SOD1 Aggregation in Amyotrophic Lateral Sclerosis via Nrf2-Mediated Autophagy Activation.2025Journal of molecular neuroscience : MN
  5. DAPK1 induces motor neuron apoptosis in hSOD1G93A-linked amyotrophic lateral sclerosis via regulating the Xiap/JNK pathway.2025Molecular and cellular neurosciences
  6. Multi-omics framework integrating genetics microbiome and immunity for understanding motor neuron degeneration pathogenesis.2025NPJ biofilms and microbiomesFree full text
  7. RBM5 induces motor neuron apoptosis in hSOD1G93A-related amyotrophic lateral sclerosis by inhibiting Rac1/AKT pathways.2024Brain research bulletin
  8. Roflupram alleviates autophagy defects and reduces mutant hSOD1-induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis.2024Neuropharmacology
  9. BRD7 regulates cellular senescence and apoptosis in ALS by modulating p21 expression and p53 mitochondrial translocation respectively.2024Neuroscience
  10. SPY1 inhibits neuronal ferroptosis in amyotrophic lateral sclerosis by reducing lipid peroxidation through regulation of GCH1 and TFR1.2023Cell death and differentiationFree full text
  11. Diphenyl diselenide protects motor neurons through inhibition of microglia-mediated inflammatory injury in amyotrophic lateral sclerosis.2021Pharmacological research
Earlier papers (2016–2020)8
  1. Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.2020Neurobiology of disease
  2. Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.2019Brain research bulletin
  3. Spy1, a unique cell cycle regulator, alters viability in ALS motor neurons and cell lines in response to mutant SOD1-induced DNA damage.2019DNA repair
  4. γ-Oryzanol mitigates oxidative stress and prevents mutant SOD1-Related neurotoxicity in Drosophila and cell models of amyotrophic lateral sclerosis.2019Neuropharmacology
  5. α-Lipoic acid attenuates oxidative stress and neurotoxicity via the ERK/Akt-dependent pathway in the mutant hSOD1 related Drosophila model and the NSC34 cell line of amyotrophic lateral sclerosis.2018Brain research bulletin
  6. Fisetin Exerts Antioxidant and Neuroprotective Effects in Multiple Mutant hSOD1 Models of Amyotrophic Lateral Sclerosis by Activating ERK.2018Neuroscience
  7. Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.2016International journal of molecular sciences
  8. Comparative Analysis of VOCs in Exhaled Breath of Amyotrophic Lateral Sclerosis and Cervical Spondylotic Myelopathy Patients.2016Scientific reports

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Harbin for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Harbin for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Harbin for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

哈尔滨医科大学附属第一医院

First Affiliated Hospital of Harbin Medical University

哈尔滨

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Affiliated Hospital of Harbin Medical College

Suggest a correctionDownload the data